Novel therapeutic strategies for ischemic heart disease

• Published in: Pharmacological research Vol. 89; pp. 36 - 45
• Main Authors: Perricone, Adam J., Vander Heide, Richard S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.11.2014
• Subjects: Animals; Cardioprotection; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cytoskeletal signaling; Cytoskeleton - drug effects; Humans; Ischemia–reperfusion; Ischemic preconditioning; Myocardial infarction; Myocardial Ischemia - drug therapy; Myocardial Ischemia - physiopathology; Reperfusion injury; Signal Transduction - drug effects; Signal Transduction - physiology; Myocardial infarction; Ischemic preconditioning; Cardioprotection; Ischemia–reperfusion; Cytoskeletal signaling; Reperfusion injury
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2014.08.004

Despite significant advances in the physician's ability to initiate myocardial reperfusion and salvage heart tissue, ischemic heart disease remains one of the leading causes of death in the United States. Consequently, alternative therapeutic strategies have been intensively investigated, especially methods of enhancing the heart's resistance to ischemic cell death – so called “cardioprotective” interventions. However, although a great deal has been learned regarding the methods and mechanisms of cardioprotective interventions, an efficacious therapy has yet to be successfully implemented in the clinical arena. This review discusses the current understanding of cardioprotection in the context of ischemic heart disease pathophysiology, highlighting those elements of ischemic heart disease pathophysiology that have received less attention as potential targets of cardioprotective intervention.